High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma

Leukemia Research

Volumn 26, Issue 3, 2002, Pages 241-248

  Niitsu, Nozomi ^a   Iijima, Kimiko ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY   (Japan)

Author keywords

International prognostic index; Non Hodgkin's lymphoma; Prognostic factor; Soluble CD44

Indexed keywords

HERMES ANTIGEN; MARKER;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD44; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036137636     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00122-9     Document Type: Article

References (34)

1. A predictive model for aggressive NHL. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
2. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family
3. Monoclonal antibodies to human lymphocyte horming receptors define a novel class of adhesion molecules in diverse cell types
4. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression
5. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
6. Expression and shedding of CD44 variant isoforms in paitients with gynecologic malignancies
7. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer
8. Serological evaluation of soluble CD44 in renal cancer
9. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia
10. Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes
11. Serum CD44 in malignant lymphoma: an association with treatment response
12. Lymphoma classification - the gap between biology and clinical management is closing
13. Report of the committee on Hodgkin's disease staging classification
14. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma
15. COP-BLAM regimen combined with granulocyte colony-stimulating factor (G-CSF) and high-grade non-Hodgkin's lymphoma
16. Individual comparisons by ranking methods
17. Evaluation of survival data and two new rank order statistics arising in its consideration
18. Regression models and life tables
19. CD44: the hyaluronan receptor
20. CD44 and its interaction with the extracellular matrix
21. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons
22. CD44: structure, function, and association with the malignant process
23. Expresion of lymphocyte horming receptor as a mechanism of dissemination in non-Hodgkin's lymphoma
24. Actived human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44
25. A strong expression of CD44-v6 correlates with shorter survival of patients with acute myeloid leukemia
26. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma
27. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer
28. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma
29. Mutations of the p53 gene as a prognostic facotr in aggressive B-cell lymphoma
30. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
31. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma
32. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma
33. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma